Director dealings

hVIVO PLC
14 June 2023
 


hVIVO plc

("hVIVO" or the "Company")

 

Director dealings

 

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) announces that it has received notification that Yamin 'Mo' Khan, Chief Executive Officer of the Company, yesterday acquired 13,526 ordinary shares of 0.1 pence each in the capital of the Company as a result of a dividend reinvestment plan. Following the purchase of shares Mo holds 523,730 ordinary shares representing approximately 0.08 per cent of the Company's issued ordinary capital.

 

For further information please contact:

 

hVIVO plc

+44 (0) 20 7756 1300

Yamin 'Mo' Khan, Chief Executive Officer

Stephen Pinkerton, Chief Financial Officer




Liberum Capital (Nominated Adviser and Joint Broker)

 +44 (0) 20 3100 2000

Ben Cryer, Edward Mansfield, Phil Walker, Will King




finnCap plc (Joint Broker)

+44 (0) 20 7220 0500

Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)




Davy (Euronext Growth Adviser and Joint Broker)

+353 (0) 1 679 6363

Anthony Farrell, Niall Gilchrist




Walbrook PR (Financial PR & IR)

Stephanie Cuthbert / Phillip Marriage /
Louis Ashe-Jepson

+44 (0) 20 7933 8780 or hvivo@walbrookpr.com

+44 (0) 7796 794 663 / +44 (0) 7867 984 082 /
+44 (0) 7747 515 393





 

Notes to Editors

 

About hVIVO

 

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

 

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Company has world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

 

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

 

 

Notification of transactions by Directors, Persons Discharging Managerial Responsibilities ("PDMRs") and persons closely associated with them.

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Yamin Khan

2.

Reason for the Notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

hVIVO plc

b)

LEI

213800VT5KBM7JLIV118

4.

Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary shares of 0.1 pence each

Identification code

ESVUFR

ISIN GB00B9275X97

b)

Nature of the Transaction

Purchase of ordinary shares pursuant to a dividend reinvestment plan

c)

Price(s) and volume(s)

Price

Volume

16.97 pence

13,526


d)

Aggregated information

-     Aggregated volume

-     Price

As above

e)

Date of the transaction

13/06/2023

f)

Place of the transaction

London Stock Exchange


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Hvivo (HVO)
UK 100

Latest directors dealings